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Male sexual di f ferent iat ion and development  proceed under  direct control  of androgens. Androgen 
action is med iated  by the intracel lu lar  androgen receptor,  which belongs to the super fami ly  of 
l igand-dependent  t ranscr ipt ion  factors. At least three pathological  situations are associated with 
abnormal  androgen receptor  s t ructure  and function: androgen insensit ivity syndrome (AIS), spinal 
and bu lbar  muscu lar  a t rophy (SBMA) and prostate cancer.  In the X- l inked androgen insensit ivity 
syndrome,  defects in the androgen receptor  gene have prevented the normal  deve lopment  of both 
internal  and external  male st ructures in 46,XY individuals. Complete or gross deletions of the 
androgen receptor  gene have not been found f requent ly  in persons with complete androgen 
insensit ivity syndrome.  Point  mutat ions  at several different sites in exons 2-8 encoding the DNA- 
and androgen-b ind ing domain,  have been repor ted  for part ia l  and complete fo rms of  androgen 
insensitivity. A relat ively high number  of  mutat ions  were repor ted  in two dif ferent clusters in exon 
5 and in exon 7. The number  of mutat ions  in exon 1 is ext remely  low and no mutat ions  have been 
repor ted  in the hinge region, located between the DNA-binding domain  and the l igand-binding 
domain  and which is encoded by the first hal f  of exon 4. Androgen receptor  gene mutat ions  in 
prostate cancer are very rare  and are repor ted  only in exons 4-8. The X-l inked spinal and bulbar  
muscle a t rophy (SBMA; Kennedy's disease) is associated with an expanded length (> 40 residues) of 
one of  the po lyg lutamine stretches in the N- termina l  domain  of the androgen receptor .  
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INTRODUCTION 
Androgens (testosterone and 5e-dihydrotestosterone) 
play a crucial role in several stages of male development 
(e.g. sexual differentiation, initiation and maintenance 
of spermatogenesis and of secondary male character- 
istics, feedback regulation of gonadotrophin secretion) 
[ 1]. Androgens act in their target cells via an interaction 
with the androgen receptor esulting in direct regu- 
lation of gene expression. The androgen receptor be- 
longs to a large family of DNA-binding zinc-finger 
proteins, which also includes the other steroid hormone 
receptors, the thyroid hormone receptors, the retinoid 
receptors and orphan receptors [2]. 
In X-linked androgen insensitivity syndrome, de- 
fects in the androgen receptor gene have prevented the 
normal development ofboth internal and external male 
structures in 46,XY individuals. The rare X-linked 
spinal and bulbar muscular atrophy is characterized by
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a progressive degeneration of motor neurons and is 
sometimes associated with signs of androgen insensitiv- 
ity and infertility [3]. Limited information is available 
on abnormal androgen receptors in prostate cancer 
[4-81. 
The information on the molecular structure of 
the human androgen receptor has facilitated the 
study of molecular defects associated with androgen 
insensitivity, SBMA and prostate cancer. 
ANDROGEN RECEPTOR ABNORMALITIES 
In this overview we will focus on the molecular 
structure of the androgen receptor in subjects with 
androgen insensitivity syndrome, in patients with 
Kennedy's yndrome (X-linked spinal and bulbar mus- 
cular atrophy), in a prostate cancer cell line (LNCaP) 
and in a tumor specimen obtained from patients with 
prostate cancer. Throughout the text, the numbering of 
the different codons is based on a total number of 910 
amino acid residues in the human androgen receptor 
(20 glutamine and 16 glycine residues). 
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ANDROGEN RECEPTOR ABNORMALITIES IN 
THE ANDROGEN INSENSITIVITY SYNDROME 
Only a few cases have been reported with partial or 
complete deletion of the androgen receptor gene, indi- 
cating the relative low frequency of this type androgen 
receptor defect [9]. Most individuals in the reported 
cases are completely androgen resistant. There has 
been no report on possible mutations in the androgen 
receptor promoter region or in the 5'- and 3'-untrans- 
lated regions of the gene. 
The N-terminal domain of the human androgen 
receptor is characterized by the presence of several 
homopolymeric amino acid stretches, e.g. three poly- 
glutamine stretches with different lengths; a long 
polyglycine stretch; a polyproline stretch of eight 
residues and a polyalanine stretch of five residues [10]. 
The length of the longest polyglutamine r peat varies 
in different normal individuals from 12 to 32 residues, 
with a high frequency of 20-22 residues [11, 12] (see 
also Fig. 1). This type of polymorphism offers the 
possibility of linkage studies in families with supposed 
defective androgen receptors. 
We have detected a single nucleotide insertion 
(codon 42, C insertion) and a single nucleotide deletion 
(codon 263, A deletion) in exon 1 in individuals with 
complete androgen insensitivity syndrome (Fig. 2). 
Both mutations caused frameshifts resulting in prema- 
ture stopcodons at codon-positions 171 and 292, re- 
spectively. In both cases androgen receptor protein 
expression was undetectable. Another mutation in exon 
1 resulted in a premature stopcodon at codon-position 
439. 
Mutations in the DNA-binding domain 
Detailed structural information has been published 
on the crystal structure of the DNA-binding domain of 
the glucocorticoid receptor complexed with DNA [13]. 
This structural information might also be representa- 
tive for the other members of the steroid/thyroid 
hormone receptor family, including the human andro- 
gen receptor. In total 18 different mutations in the 
DNA-binding domain (exons 2 and 3) have been 
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Fig. 1. Posit ion of the glutamine (Gin) stretch in the 
aminoterminal  domain of the human androgen receptor, 
which is susceptible to variation in normal  individuals. The 
abnormal  length of the Gin-stretch associated with the X- 
l inked spinal and bulbar muscular  atrophy (SBMA) is also 
indicated. 
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Fig. 2. Schematic  representation of the localization of andro- 
gen receptor mutations detected in Rotterdam in patients 
with the complete (CAIS) and partial (PAIS) form of andro- 
gen insensitivity. Numbers and one letter codes indicate the 
position and the type of substitution of the mutated codons. 
published (Fig. 3). Eight mutations were observed in 
the first zinc finger and ten in the second zinc finger. 
In genital skin fibroblasts from a subject with the 
X-linked Reifenstein syndrome (partial androgen in- 
sensitivity) we detected the presence of two mature 
androgen receptor transcripts; the wild-type transcript 
and a transcript in which exon 3 sequences were absent 
without disruption of the translational reading frame 
[23]. Sequence analysis howed a deletion of > 6 kb in 
intron 2 of the human androgen receptor gene ending 
18 bp upstream of exon 3 (Fig. 4). The deletion in- 
cluded the putative branch-point sequence but not the 
acceptor splice site on the intron 2/exon 3 boundary. 
The deletion results in 92% aberrant splicing of wild- 
type transcript. The mutant transcript encodes an 
androgen receptor protein lacking the second zinc 
finger of the DNA binding domain. The mutant pro- 
tein was expressed in genital skin fibroblasts of the 
patient. The residual 8% wild-type transcript could be 
the result of the use of a cryptic branch-point sequence 
located 63 bp upstream of the intron 2/exon 3 boundary 
of the mutant gene. The mutant androgen receptor 
protein was not able to activate transcription and did 
not influence the transactivating properties of the wild- 
type androgen receptor. It is concluded that the partial 
androgen-insensitivity syndrome of this patient is the 
consequence of the limited amount of wild-type andro- 
gen receptor protein expressed in androgen target cells, 
resulting from the deletion of the intron 2 putative 
branch-point sequence. A complete deletion of exon 3 
has been reported in a patient with complete androgen 
insensitivity [9]. 
Mutations in the androgen binding domain 
Several functional and structural aspects have been 
ascribed to exon 4, which harbors part of a highly 
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Fig. 3. Location of the different amino  acid subst i tut ions in the DNA-b ind ing domain  due to point mutat ions  
in exons 2 and 3 and two deletions of a codon (A) in the androgen receptor  gone of indiv iduals  with complete 
(CAIS) or part ia l  (PAIS) androgen insensit iv ity [refs 14-22 and unpubl i shed observations].  
conserved nucleoplasmin-like nuclear localization sig- 
nal, the hinge region and part of the steroid binding 
domain [24]. Therefore mutations in exon 4 could 
affect different functions of the androgen receptor. All 
reported mutations to date in exon 4 are located in the 
part of the exon that encodes the N-terminal region of 
the steroid binding domain. 
We detected in the sequence of the androgen recep- 
tor gone from a person with the complete form of 
androgen insensitivity a G to T mutation on position 
1 in the splice donor site of intron 4 [25]. The conse- 
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Fig. 4. Schemat ic  i l lustrat ion of exons 2-4 of the human 
androgen receptor  gone and of the a l ternat ive splicing event 
resul t ing f rom a part ia l  intron 2 deletion in a pat ient  with the 
X-l inked Rei fenstein syndrome. The solid l ines represent  
wi ld-type splicing events and the dashed line represents  the 
aber rant  spl icing event [ref. 23]. 
quence of this point mutation was an abnormal andro- 
gen receptor mRNA splicing. Sequence analysis of the 
mutant fragment revealed the use of a cryptic splice 
donor site CAG/GTGTAG at position 2020/2021 in 
exon 4 of the human androgen receptor gone which is 
normally inactive. The use of this cryptic splice site 
results in the deletion of 123 nucleotides from the 
mRNA.  Translation will consequently result in an 
in-frame deletion of 41 amino acid residues in the 
androgen receptor protein from this person. Transient 
expression of the mutant androgen receptor esulted in 
the synthesis of a protein which was approx. 5 kDa 
smaller than the wild type receptor as determined by 
SDS-PAGE.  The mutant receptor was unable to bind 
androgens and did not activate transcription of an 
androgen-regulated reporter gone construct [25]. 
In two unrelated individuals with the complete form 
of androgen insensitivity, two different point mutations 
were found by us at the same nucleotide in codon 686 
(aspartic acid) of exon 4 [26] (Fig. 2). Both mutant 
androgen receptors displayed the same altered binding 
characteristics after transient expression as those 
measured in genital skin fibroblasts from the affected 
subjects. In co-transfection studies, using a glucocorti- 
coid responsive lement linked to the thymidine kinase 
promoter and to the chloramphenicol acetyl transferase 
gone (GRE- tk -CAT)  as a reporter gene, both mutant 
receptors were devoid of any transactivation activity in 
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the presence of physiological hormone concentrations 
[26]. 
Exon 5 forms an essential part of the steroid-binding 
domain of the androgen receptor. We detected 5 differ- 
ent mutations in exon 5, of which the M733V and 
M736T mutations were found in patients with the 
partial form of the androgen insensitivity syndrome 
(Fig. 2). In exon 5 a total of 25 point mutations in 20 
different codons have been reported. Two clusters of 
mutations can be localized in exon 5 between codons 
723-732 and 740-757 in the androgen receptor gene of 
patients with the complete androgen insensitivity syn- 
drome. We found three mutations (W742R; R743Q; 
F7551) located in the second cluster (Fig. 2). 
The 10 reported mutations in exon 6 in 9 different 
codons have been found in androgen receptor genes 
from androgen insensitive individuals with the 
complete form (6 mutations) and the partial form 
(4 mutations) of the syndrome. 
For exon¢7 twelve mutations in eight different codons 
have been reported in persons with the complete andro- 
gen insensitivity syndrome, while 7 mutations were 
reported in the androgen receptor gene of persons with 
partial androgen insensitivity. In addition we detected 
in a patient with the complete syndrome an insertion of 
one nucleotide in codon 839 causing a frame-shift and 
resulting in a premature stopcodon (Fig. 2). From 
mutational analysis tudies it is known that this kind of 
receptor truncation completely abolishes hormone 
binding and transcriptional activation [27]. 
In total ten mutations in exon 8 have been reported. 
Six mutations were found in subjects with the complete 
form of androgen insensitivity and 4 mutations in 
subjects with the partial form. 
ANDROGEN RECEPTOR ABNORMALITIES IN 
SPINAL AND BULBAR MUSCULAR ATROPHY 
(SBMA) 
A unique example of tissue specific effects of a 
defective androgen receptor is Kennedy's syndrome. 
This rare, X-l inked motor neuron disease becomes 
manifest in men between the age of 30 and 50 and 
is characterized by a progressive spinal and bulbar 
muscular atrophy associated with signs of androgen 
insensitivity and infertility [3]. The length of the 
polyglutamine stretch in the androgen receptor in 
all investigated Kennedy's syndrome patients ranges 
between 40 and 52 [11]. 
We have investigated the effect of an expanded 
polyglutamine stretch and also a completely deleted 
glutamine stretch on the transactivation function of the 
androgen receptor in a model system. For this purpose 
the androgen receptor constructs were expressed after 
cotransfection of COS cells with a reporter gene con- 
struct containing either the mouse mammary tumor 
virus promoter (MMTV)  or the prostate-specific anti- 
gen (PSA) promoter [28]. In these experiments a 2-fold 
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Fig. 5. Influence of the length of the polyglutamine-stretch on 
transcription activation by the human androgen receptor. 
Transcriptional activity was examined by co-transfection f
androgen receptor expression plasmids and reporter plas- 
mids containing either the MMTV promoter or the promoter 
of the prostate specific antigen gene (PSA) linked to the 
CAT-gene. CAT activity induced by the wild-type androgen 
receptor in the presence of 10 nM methyltrienolone (R1881) 
was arbitrarily set at 100%. 
reduction in transcription activation was observed with 
both reporter-constructs and the androgen receptor 
with 48 glutamine residues (Fig. 5). Complete deletion 
of the glutamine stretch resulted in a significant in- 
crease in transcriptional regulation only with the PSA- 
reporter construct. The differences could not be 
explained by differences in the level of receptor protein 
expression. In similar studies Mhatre et al. also found 
that an androgen receptor with an expanded poly- 
glutamine stretch transactivates ubnormally [29]. 
Whether a doubling of the length of the polyglutamine 
stretch directly affects motor neuron function is still 
unclear. Possibly a change in the structural constraint 
of the N-terminal domain could result in a modified 
interaction with motor neuron-specific transcription 
factors and consequently in an altered assembly of the 
transcription initiation complex. 
ANDROGEN RECEPTOR ABNORMALITIES IN 
PROSTATE CANCER 
It has long been speculated that mutations in the 
androgen receptor could play a role in the initiation or 
the progressive androgen-independent growth of 
prostate tumors. Previous studies have established that 
the human prostate carcinoma cell line LNCaP can be 
stimulated with respect o growth not only by andro- 
gens, but also by progesterone, R5020 (a synthetic 
progestagen) and oestradiol [30]. Characterization of 
the androgen receptor in these cells revealed an altered 
steroid binding specificity with an increased preference 
for progestagens and oestradiol as compared with the 
steroid binding specificity of the androgen receptor in 
normal cells [31]. These data strongly suggested a 
modification of the androgen receptor and particularly 
in the steroid-binding domain. Sequence analysis re- 
vealed one point mutation in codon 868 in exon 8 
Androgen Receptor Mutations 447 
mm ,,m 
18 Gin 
24 Gin 
Gin -> GIu 
789 
Val -> Met 
721 
Le u69>2 H i~  s STEROID 
Val -> Met 
706 
910 
Thr -> Ala 
868 
Fig. 6. Location of androgen receptor mutat ions publ ished in 
prostate cancer. Numbers  and one letter codes refer to the 
position and the type of substitution of the mutated codons 
[refs 4, 5, 7, 32]. 
located at the C - te rmina l  end  o f  the  stero id  b ind ing  
domain  [32] (F ig.  6). The  mutat ion  (A--~ G)  resu l ted 
in a threonine- - - ,  a lan ine subst i tut ion .  To  determine  
whether  the subst i tu t ion  affects the funct iona l  p roper -  
t ies o f  the LNCaP androgen receptor ,  the mutant  
cDNA was c loned in an express ion  vector  and t rans i -  
ent ly  expressed  in COS-1  and HeLa  cells. In  the 
t rans fect ion  studies,  the mutant  receptor  d isp layed 
increased b ind ing  aff inity for p rogestagens  and oestra-  
diol.  In  add i t ion ,  these l igands act ivate t ranscr ip t ion  at 
concent ra t ions  wh ich  are not  suff ic ient for act ivat ion  of  
the w i ld - type  androgen receptor .  These  results  conf i rm 
that the observed  po in t  mutat ion  in the LNCaP andro -  
gen receptor  is the cause of  the broad  stero id b ind ing  
specif ic ity.  Whether  such a po int  mutat ion ,  wh ich  
changes  the stero id  b ind ing  speci f ic i ty,  can p lay a role 
in p rogress ive  prostate  tumor  growth  remains  to be 
establ ished.  
Ana lys is  o f  the s t ruc ture  o f  the androgen receptor  in 
27 DNA samples  o f  pat ients  w i th  progress ive ly  advanc-  
ing prostate  cancer  d id  not  result  in the detect ion  of  
mutat ions  [6]. In  s imi lar  studies by others ,  three di f fer-  
ent  po in t  mutat ions  were  detected  in the stero id  b ind-  
ing domain  [4, 5, 7] (F ig.  5). In  one case the amino  acid 
subst i tu t ion  resu l ted in an a l tered stero id  b ind ing  
speci f ic i ty s imi lar ly  as was found  for the LNCaP cell  
androgen receptor  [5]. The  same mutat ion  as found  in 
the LNCaP cell  androgen receptor  has been  repor ted  in 
metastat ic  t issues f rom a prostate  cancer  pat ient  [7]. 
A lso  a var ia t ion  in the po lymorph ic  g lu tamine-s t re tch  
has been repor ted  in tumor  t issue f rom a prostate  
cancer  pat ient  [8]. I t  can be conc luded  that,  a l though 
the androgen receptor  is one of  the key molecu les  in 
prostate  deve lopment ,  the mutat ions  of  the receptor  do 
not  substant ia l ly  cont r ibute  to aber rant  cell  g rowth  in 
the case of  prostate  cancer.  
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